Association of Ex Vivo Drug Response (EVDR) and Clinical Outcome in Ovarian Cancer (EXCYTE-1)
Observational Analysis of the Association of Drug Activity Measured in Viable Tumour Tissues ex Vivo and Clinical Response in Ovarian Cancer: A Basic Research Study
Sponsor: AGO Research GmbH
Terminated
Study was terminated due to a strategic re-evaluation of the company's overall business and clinical development strategy.
Other terminated trials from AGO Research GmbH
More terminations from AGO Research GmbH
Listed as NCT06068738, this observational or N/A phase trial focuses on Epithelial Ovarian Cancer and remains terminated or withdrawn. Sponsored by AGO Research GmbH, it has been updated 5 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
5 versions recorded-
Oct 2024 — Present [monthly]
Terminated
Status: Recruiting → Terminated
-
Sep 2024 — Oct 2024 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Feb 2024 — Jul 2024 [monthly]
Recruiting
-
Nov 2023 — Feb 2024 [monthly]
Recruiting
First recorded
Apr 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AGO Research GmbH
- Exscientia AI Limited
For direct contact, visit the study record on ClinicalTrials.gov .